Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Non-Current Debt (2016 - 2026)

Phibro Animal Health has reported Non-Current Debt over the past 13 years, most recently at $107.0 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 6.14% year-over-year to $107.0 million; the TTM value through Dec 2025 reached $107.0 million, down 6.14%, while the annual FY2025 figure was $615.4 million, 118.02% up from the prior year.
  • Non-Current Debt for Q4 2025 was $107.0 million at Phibro Animal Health, down from $609.5 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $619.2 million in Q1 2025 and troughed at $95.0 million in Q2 2021.
  • A 5-year average of $274.6 million and a median of $274.8 million in 2022 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: tumbled 61.73% in 2024 and later surged 240.51% in 2025.
  • Year by year, Non-Current Debt stood at $107.0 million in 2021, then soared by 71.96% to $184.0 million in 2022, then soared by 61.88% to $297.9 million in 2023, then tumbled by 61.73% to $114.0 million in 2024, then decreased by 6.14% to $107.0 million in 2025.
  • Business Quant data shows Non-Current Debt for PAHC at $107.0 million in Q4 2025, $609.5 million in Q3 2025, and $615.4 million in Q2 2025.